What stage does LYFE Capital invest at?

LYFE Capital invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.

Where is LYFE Capital located?

LYFE Capital is headquartered in Menlo Park, US.

Does LYFE Capital lead rounds?

LYFE Capital typically participates in rounds rather than leading them.

LYFE Capital

Venture capital

Menlo Park · Seed–Late Stage · 17 people tracked

Also known as LYFE CAPITAL GLOBAL PARTNER LIMITED · LYFE CAPITAL INVESTMENT MANAGEMENT (HONG KONG) LIMITED · LYFE CAPITAL INVESTMENT MANAGEMENT (SHANGHAI) CO., LTD. · LYFE CAPITAL INVESTMENT MANAGEMENT LIMITED · LYFE U.S LLC

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

LYFE Capital is a healthcare investment platform led by investment veterans and operators who have navigated multiple market cycles. Operating from five global offices in Asia and the United States, the firm targets critical healthcare supply chain assets, specialized product platforms, and next-generation R&D services. Its aim is to help these companies grow significant and resilient revenues by tapping into global mature markets.

Invests inBiotech Digital Health Healthtech Medical Devices Robotics Sector AgnosticAsia-PacificChinaGrand CaymanJapanMenlo ParkNorth AmericaShanghaiSingaporeSouth KoreaUnited States

Source: firm website, verified Aug 11, 2026.

Stage

Seed–Late Stage

Menlo Park, US

Leads rounds

Follows

Instruments

Equity

Founded

2015

AUM

$2B

VC funds

Tracked investments

Team · 17 people

from the firm's website & public directories

James Zhao· Founder and Partner· New Jerseyin

James Zhao focuses on healthcare supply chains across US and Asia, enabling multi-site networks and helping Asian healthcare firms expand globally through hands-on deals, cross-border partnerships, and co-investments for LPs.

j•••@lyfecapital.comreveal

Alan Wang· Managing Director· Singapore

Singapore-based, Alan Wang combines Bristol Myers Squibb corporate strategy and healthcare consulting experience to lead cross‑border Asia–U.S. medtech deals (Kangji, EDGE, Noah, Fong's Engineering) with a data‑driven analytical approach.

Frances Chovanec· Managing Director· New York Cityin

Frances Chovanec combines leading Kangji Medical’s IPO as CFO/Executive Director with investment banking at Morgan Stanley and Goldman Sachs, Fosun MD for U.S. private equity, and running her advisory firm.

Peter Lee· Managing Director· New Jerseyin

Peter Lee applies public-equity rigor and crossover data analysis to earlier-stage deals, sits on an unusually high number of portfolio boards as an early-career investor, and samples widely across healthcare.

William Chen· Partner· Singaporein

William Chen brings hands-on operating experience—seconded into portfolio company IMEIK Technology to lead business development and strategic investments—and leads cross‑border medical aesthetics between Japan, Korea and China.

Yao Li Ho· Managing Director· California and Tokyoin

Yao Li Ho, since 2015, bridges U.S. and Asian healthcare, combining biomedical engineering and R&D experience with international pharma business development and operating from Tokyo and California offices.

Derek Yuan· Partner· San Francisco Bay Area

Derek Yuan, Menlo Park–based with a Ph.D. in Chemical Biology and Tsinghua degrees in chemistry and biology, focuses on cross-border healthcare investing, sits on Iecure’s board, and speaks at conferences

d•••@lyfecapital.comreveal

Jack Chen· Partner· Singaporein

Jack Chen is a Singapore‑based healthcare investor with clinical training from Fudan and an MBA from Kellogg, leading Asia‑Pacific investments while overseeing deal quality, portfolio management and talent development.

Sameer Rohatgi· Partner· San Diegoin

Sameer Rohatgi, founding executive at Helixis (acquired by Illumina) who led Illumina’s international corporate and business development, takes board seats when his firm leads rounds to help diagnostics scale globally.

s•••@lyfecapital.comreveal

Alvin Koh· Investment Principal and Senior Director, APAC Business Development· Singaporein

Alvin Koh spent 14 years at Illumina building life‑science tools and APAC healthcare market expertise, and combines investing and a business development mandate to act as a structured regional partner.

Jing Xu· Principal

With a PhD in pharmaceutical sciences, Jing Xu spans big‑pharma commercialization, corporate development, venture and operator roles at Sciwind, backing Asian biotechs into global partners like MediLink and ProfoundBio.

Yoshitaka Nagai· Principal· Japanin

Yoshitaka Nagai has 10+ years in Nomura healthcare banking—led CRO mergers including a ~JPY1 trillion deal—and serves as a Japan bridge, sourcing and executing investments in pharma, med‑tech, pharma services.

Fong Ming Koh· Principal· Singaporein

Fong Ming Koh, a UCSF-trained developmental biologist with deep expertise in stem cells, epigenetics and cancer biology, pairs Asia-focused biopharma investing with hands-on Singapore ecosystem building and conference leadership.

f•••@lyfecapital.comreveal

David Liu· Director of Investor Relations· Singapore

Director of Investor Relations leading strategy, fundraising, investor relations, and internal portfolio review. Previously grew a medical aesthetic clinic chain and founded a cross-cultural media company; holds a Columbia MBA.

Laura Lu· Chief Legal Officer· New Jerseyin

Chief Legal Officer with over 30 years of legal experience across fund formation, transactions, and compliance, also serving as ESG coordinator. Previously Legal Director at MSD China and Senior Legal Counsel at Siemens China.

Roy Xu· Chief Financial Officer· Shanghai and California

Chief Financial Officer with over 20 years of financial expertise managing LYFE's finance operations, strategy, fundraising, and budgeting. Previously a VP at GP Capital and worked at PwC; a CPA charterholder.

Vivien Li· Director of Business Development

Director of Business Development driving value creation for portfolio companies through operational improvement and post-deal management. Formerly founded a healthcare company and was a founding member of a China-focused early-stage healthcare VC firm; holds a CUHK MBA.

Investments · 16 tracked

founders shown can be your intro path

Bora Pharmaceuticals

Global-focused drug development and manufacturing company with capabilities in M&A integration, CDMO operations, and commercial operations in North America.

Brightech

New Jersey-based end-to-end data service CRO leveraging Asia to improve operational efficiency.

ChemLex

EDGE

Edge Medical

China-based surgical robotics company with approvals for both multi-port and single-port endoscopy systems.

Fong's Engineering

Singapore-based specialized MedTech contract development and manufacturing organization (CDMO) with a strong foothold in the endoscopic sector.

IMEIK Technology

Chinese healthcare company (SZ.300896) where LYFE led business development and strategic investments.

Jeisis Medical

South Korean energy-based medical aesthetic device company with diversified product lines and fast iteration.

Kali Therapeutics

Kangji Medical

Medical device company in China's minimally invasive surgery market; LYFE Fund I portfolio company taken public.

MediLink

First-in-class ADC platform partnered with Roche and BioNTech.

Noah

Noah Medical

California-based surgical robotics company focused on endoluminal robotics.

Profound Bioprofoundbio.com

Sciwind

Leading biotech focused on obesity.

ST Pharm

South Korean CDMO player in the global oligonucleotide synthesis market with partnerships including GSK, Novartis, Roche, and BMS.

Frequently asked questions

What stage does LYFE Capital invest at?: LYFE Capital invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What sectors does LYFE Capital focus on?: LYFE Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices, Robotics, Sector Agnostic.
Where is LYFE Capital located?: LYFE Capital is headquartered in Menlo Park, US.
Does LYFE Capital lead rounds?: LYFE Capital typically participates in rounds rather than leading them.

Similar investors

DCVC (Data Collective)

DCVC (Data Collective) is a venture capital firm that backs founders building companies which apply technology to major challenges across areas such as energy, biotech, agriculture, and machine learning.

$5M – $25M

GV (Google Ventures)

GV (formerly Google Ventures) is a venture investment firm that backs founders across many industries, aiming to build long-term relationships and support companies across multiple stages and milestones.

$250K – $50M

Khosla Ventures

Khosla Ventures is a venture capital firm known for backing bold, contrarian bets in world-class teams that can reshape entire industries.

$5K – $50M

Kleiner Perkins

Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, with a portfolio of companies from early stage through growth.

$500K – $15M

Basecamp Fund

A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.

$100K – $10M